Open Access

Benefits of adjuvant treatment with the Pingxiao capsule in patients with early breast cancer: A single‑center retrospective cohort study

  • Authors:
    • Shuo Wang
    • Caiwei Zheng
    • Lei Zhao
    • Haiyang Jiang
    • Xinyu Zheng
  • View Affiliations

  • Published online on: June 12, 2024     https://doi.org/10.3892/ol.2024.14499
  • Article Number: 366
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Early breast cancer (EBC) is cancer that has not spread beyond the breast or the axillary lymph nodes. The present retrospective cohort study investigated the efficacy and safety of the Pingxiao capsule (PXC), which contains a formula of traditional Chinese herbs, as adjuvant therapy in patients with EBC in a single Chinese academic medical center. Patients with EBC who had received surgery and chemotherapy were analyzed and divided into the PXC and non‑PXC groups. Disease‑free survival (DFS) time, overall survival (OS) time, demographic characteristics and adverse events were examined. Kaplan‑Meier survival curves were used to compare the differences in DFS and OS. A total of 371 participants with a median age of 54 years were included in this study. The median DFS time of all patients was 101 months. The overall DFS rate was 72.1% in the PXC group compared with 63.6% in the non‑PXC group. For women with hormone receptor‑negative tumors, the DFS rate in the PXC group was significantly higher than that in the non‑PXC group, irrespective of node status. Adjuvant treatment with PXC for ≥3 months was associated with significantly longer median DFS time compared with that in the non‑PXC group. In addition, the incidence of neutropenia rated to be grade 2 or higher was significantly lower in the PXC group compared with that in the control group, and a markedly, but non‑significantly, lower prevalence of nausea was observed in PXC group (0 vs. 4.1%). In conclusion, PXC as an adjuvant therapy along with chemotherapy is associated with prolonged DFS times in patients with EBC when compared with chemotherapy alone. The therapeutic value of combined PXC and systemic chemotherapy should be further elucidated by rigorous prospective clinical trials.
View Figures
View References

Related Articles

Journal Cover

August-2024
Volume 28 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang S, Zheng C, Zhao L, Jiang H and Zheng X: Benefits of adjuvant treatment with the Pingxiao capsule in patients with early breast cancer: A single‑center retrospective cohort study. Oncol Lett 28: 366, 2024.
APA
Wang, S., Zheng, C., Zhao, L., Jiang, H., & Zheng, X. (2024). Benefits of adjuvant treatment with the Pingxiao capsule in patients with early breast cancer: A single‑center retrospective cohort study. Oncology Letters, 28, 366. https://doi.org/10.3892/ol.2024.14499
MLA
Wang, S., Zheng, C., Zhao, L., Jiang, H., Zheng, X."Benefits of adjuvant treatment with the Pingxiao capsule in patients with early breast cancer: A single‑center retrospective cohort study". Oncology Letters 28.2 (2024): 366.
Chicago
Wang, S., Zheng, C., Zhao, L., Jiang, H., Zheng, X."Benefits of adjuvant treatment with the Pingxiao capsule in patients with early breast cancer: A single‑center retrospective cohort study". Oncology Letters 28, no. 2 (2024): 366. https://doi.org/10.3892/ol.2024.14499